Home/Pipeline/Espindolol (MT-102)

Espindolol (MT-102)

Cancer Cachexia

Phase 2/Spin-outActive

Key Facts

Indication

Cancer Cachexia

Phase

Phase 2/Spin-out

Status

Active

Company

Numedicus

About Numedicus

Numedicus is a private, UK-based biotech firm specializing in the systematic identification of new uses for existing drugs through its extensive, experimentally validated database. Founded in 2015, the company employs a virtual model, collaborating with partners to advance repurposed candidates through clinical development, as evidenced by its portfolio of licensed programs. Led by industry veteran David Cavalla, Numedicus targets significant unmet medical needs across diverse therapeutic areas, offering a de-risked and capital-efficient approach to drug development.

View full company profile

Therapeutic Areas

Rare Diseases Oncology Supportive Care Infectious Disease Neurology

Other Cancer Cachexia Drugs

Drug	Company	Phase	Status
NGM120	NGM Biopharmaceuticals	Phase 2	Active
Mifomelatide (TCMCB07)	Endevica Bio	Phase 2	Active
Rilogrotug (AV-380)	AVEO Oncology	Phase 1/2	Active
S-pindolol benzoate (ACM-001.1)	Actimed Therapeutics	Phase 2	Active